1. Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States.
- Author
-
Nargesi, Arash, Clark, Callahan, Aminorroaya, Arya, Chen, Lian, Liu, Mengni, Reddy, Abraham, Amodeo, Samuel, Oikonomou, Evangelos, McGuire, Darren, Lin, Zhenqiu, Inzucchi, Silvio, Khera, Rohan, and Suchard, Marc
- Subjects
Aged ,Humans ,United States ,Hypoglycemic Agents ,Diabetes Mellitus ,Type 2 ,Sodium-Glucose Transporter 2 Inhibitors ,Glucagon-Like Peptide-1 Receptor ,Medicare - Abstract
Selected glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have cardioprotective effects in patients with type 2 diabetes mellitus (T2D) and elevated cardiovascular risk. Prescription and consistent use of these medications are essential to realizing their benefits. In a nationwide deidentified United States administrative claims database of adults with T2D, the prescription practices of GLP-1RAs and SGLT-2i were evaluated across guideline-directed co-morbidity indications from 2018 to 2020. The monthly fill rates were assessed for 12 months after the initiation of therapy by calculating the proportion of days with consistent medication use. Of 587,657 subjects with T2D, 80,196 (13.6%) were prescribed GLP-1RAs and 68,149 (11.5%) SGLT-2i from 2018 to 2020, representing 12.9% and 11.6% of patients with indications for each medication, respectively. In new initiators, 1-year fill rate was 52.5% for GLP-1RAs and 52.9% for SGLT-2i, which was higher for patients with commercial insurance than those with Medicare Advantage plans for both GLP-1RAs (59.3% vs 51.0%, p
- Published
- 2023